- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04958889
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective observational study being conducted to learn about late (2+ weeks or more) effects of COVID-19 in people living with and without HIV. The investigators plan to do this by studying people who have COVID-19 and people who have not had COVID-19, and by studying people living with HIV and people who are HIV-negative. The investigators will investigate the average duration of symptoms after COVID-19, how these symptoms affect quality of life, and what medical complications are common after COVID-19 in people with and without HIV.
Participation involves:
- Participant completion of surveys about themselves, their health history, their quality of life and mood in the recent past, and about COVID-19 or HIV if the participant has a history of either infection. The investigators will ask participants to answer questions in up to 5 follow-up surveys over the course of a year about their symptoms, mood, quality of life, and changes in health. Participants will also complete a series of short tests of thinking, memory, and reaction speed at certain follow-up surveys.
- Up to two visits to the participant's home (or an acceptable location of their choosing) by a phlebotomist. The phlebotomist will collect about 3.5 tablespoons of blood, as well as measure height, weight, and vital signs when laying down and standing up.
This is a fully remote study and all study activities can be done from home or another location of the participant's choosing.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Nuria Gallego Marquez, MSPH
- Phone Number: 4439614681
- Email: covidrecovery@jhmi.edu
Study Contact Backup
- Name: Annie Antar, MD, PhD
- Phone Number: 4439614681
- Email: covidrecovery@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Investigators will recruit volunteers with and without HIV and with and without a COVID-19 diagnosis from across the contiguous 48 US states in the following numbers:
- 110 adult people living with HIV (PWH) with COVID-19 symptom onset or first positive test within the prior 4 weeks
- 110 adult HIV-negative people with COVID-19 symptom onset or first positive test within the prior 4 weeks
- 45 adult PWH with no history of COVID-19
- 50 adult HIV-negative people with no history of COVID-19
Investigators aim to enroll a population of PWH that is roughly representative of the demographic and geographic diversity of PWH across the United States.
Description
Inclusion Criteria:
- Adults 18 years of age or older
- Living within the contiguous 48 states
- Groups 1 and 3: self-reported HIV infection
- Groups 2 and 4: self-reported HIV negative
Exclusion Criteria:
- Inability to communicate by telephone in English or Spanish
- Inability to complete required study events
- A first or only diagnosis of COVID-19 5 or more weeks prior to first contact with participant
- Groups 3 and 4: diagnosis of cOVID-19 ever, or participant suspects they had COVID-19 at any time regardless of whether they were tested
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV+ adults with recent COVID-19 diagnosis
Required study visits:
Optional study visits: • Follow up questionnaire at month 2, month 6, and month 12 |
(observational study)
|
HIV- adults with recent COVID-19 diagnosis
Required study visits:
Optional study visits: • Follow up questionnaire at month 2, month 6, and month 12 |
(observational study)
|
HIV+ adults with no history of COVID-19
Required study visits:
Optional study visits: • Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire. |
(observational study)
|
HIV- adults with no history of COVID-19
Required study visits:
Optional study visits: • Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire. |
(observational study)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptom severity after COVID-19 infection over 12 months after infection
Time Frame: 1, 2, 4, 6 and 12 months
|
Time to return to usual health and activities, as measured using the Influenza Patient-reported Outcome (Flu-PRO) instrument.
The overall score is calculated as the mean across 32 items, and ranges from 0 (symptom free) to 4 (very severe symptoms).
|
1, 2, 4, 6 and 12 months
|
Change in fatigue severity
Time Frame: 1 and 4 months
|
Presence/absence of fatigue post-symptom onset, severity of fatigue and its effect on activity level as measured using the Fatigue Severity Scale.
The Fatigue Severity Scale is a 9-item tool and each item is ranked from 1 (strongly disagree) to 7 (strongly agree).
The item scores are added to generate the overall score, ranging from 9 (least severe) to 63 (most severe).
|
1 and 4 months
|
Change in number of COVID-19 symptoms experienced over 12 months after infection
Time Frame: 1, 2, 4, 6 and 12 months
|
Number of symptoms experienced using Flu-PRO and additional COVID-19 specific symptoms in domains of neuropsychiatry, cardiovascular, and skin.
Flu-PRO scores range from 0 (symptom free) to 4 (very severe symptoms).
|
1, 2, 4, 6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mMRC rates of dyspnea
Time Frame: 1 and 4 months
|
The Modified Medical Research Council (mMRC) instrument will be used to measure dyspnea.
The mMRC rates severity of dyspnea on a scale of 0 to 4, 4 indicating the highest level of dyspnea severity.
|
1 and 4 months
|
Change in cognitive function (learning and memory) as measured by the RAVLT from month 1 to month 4
Time Frame: 1 and 4 months
|
Learning and memory assessed through the Rey Auditory Verbal Learning Test (RAVLT), in which participants receive a total learning score (range 0-36), a delayed recall score (range 0-12) and a recognition score (range -12 - +12).
In all cases, a higher score indicates better recall.
|
1 and 4 months
|
Change in cognitive function (attention and executive function) as assessed through oral trail tests from month 1 to month 4
Time Frame: 1 and 4 months
|
Attention and executive function assessed through an oral trail test, in which participants are timed between 0 and 300 seconds.
A higher time indicates lower attention and executive function.
|
1 and 4 months
|
Change in cognitive function (attention and working memory) as assessed through digit span tests from month 1 to month 4
Time Frame: 1 and 4 months
|
Attention and working memory assessed through a digit span task-forward and backward test.
The forward test is scored from 0-16 and the backward test from 0-18, higher scores indicating better attention and memory.
|
1 and 4 months
|
Change in cognitive function (phonemic and semantic fluency) as assessed through letter and category-guided fluency tests from month 1 to month 4
Time Frame: 1 and 4 months
|
Phonemic and semantic fluency assessed through a letter-guided and category-guided fluency test.
Scores range from 0-100, with a higher score indicating increased fluency.
|
1 and 4 months
|
Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia
Time Frame: 1 month
|
Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting).
|
1 month
|
Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia
Time Frame: 4 months
|
Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting).
|
4 months
|
Change in PHQ-9 depression symptoms
Time Frame: 1 and 4 months
|
Self-reported measure of depressive symptoms using The Patient Health Questionnaire (PHQ-9).
The PHQ-9 is a 9 item scale with a score range of 1-27 with higher scores indicating severe depression.
|
1 and 4 months
|
Change in quality of life as assessed using the Short Form-36
Time Frame: 1 and 4 months
|
Quality of life in the domains of vitality, physical functioning, bodily pain, general health perceptions, physical and emotional and social role functioning, as assessed using the Short Form-36.
The Short Form-36 measures physical and mental health using 8 scales.
The final score ranges from 0 (worse health status) to 100 (better health status).
|
1 and 4 months
|
Change in insomnia as assessed using the Insomnia Severity Index from month 1 to month 4
Time Frame: 1 and 4 months
|
Presence, severity, and patterns of insomnia, and its interference with daily functioning as assessed by the Insomnia Severity Index.
The Insomnia Severity Index is a 7 item scale with a score range of 0-28.
A higher score indicates severe insomnia.
|
1 and 4 months
|
Change in anxiety as assessed using the GAD-7 from month 1 to month 4
Time Frame: 1 and 4 months
|
Self-reported measure of anxiety using The Generalized Anxiety Disorder (GAD-7).
The GAD-7 is a 7 item instrument used to measure or assess anxiety disorders.
The score range is from 0-21.
A higher score indicates severe anxiety.
|
1 and 4 months
|
Change in overall mental health as assessed using the CAT-MH from month 1 to month 4
Time Frame: 1 and 4 months
|
Self-reported measures of mental health symptoms (anxiety and depression) using the Computer Adaptive Test-Mental Health (CAT-MH).
Scores range from 0-100, with a higher score indicating more severe symptoms.
|
1 and 4 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
New self-reported diagnoses over 12 months after COVID-19 infection
Time Frame: 1, 2, 4, 6 and 12 months
|
New medical diagnoses after COVID-19 infection.
|
1, 2, 4, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Annie Antar, MD,PhD, Infectious Disease - Broadway
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Chronic Disease
- Post-Infectious Disorders
- Severe Acute Respiratory Syndrome
- COVID-19
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- IRB00278774
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
Medical Corps, Israel Defense ForceUnknownMusculoskeletal Disorders | Upper Extremity Pain ChronicIsrael